Author

Emilia Sardo

Observed names: E. Sardo, E.G. Sardo, Emilia Gabriela Sardo

Institution: Hospital Universitari de Vic

Observed institutions: Universitat de Vic - Universitat Central de Catalunya, University of Campania "Luigi Vanvitelli", Vall d'Hebron Hospital Universitari, Hospital Universitari de Vic, Candiolo Cancer Institute, Fundacion Allende

ORCID: 0000-0002-1764-0528

Observed ORCID: 0000-0002-1764-0528

OpenAlex ID: A5046005215

Association between night-time surgery and occurrence of intraoperative adverse events and postoperative pulmonary complications

2019 · A. Cortegiani, C. Gregoretti, et al. · British Journal of Anaesthesia · 74

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer

2021 · Javier Ros, Iosune Baraibar, et al. · Therapeutic Advances in Medical Oncology · 70

Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data

2022 · Emilia Sardo, Stefania Napolitano, et al. · Journal of Personalized Medicine · 27

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update

2020 · Iosune Baraibar, Javier Ros, et al. · Expert Review of Molecular Diagnostics · 13

Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia

2024 · Marta Parera Roig, David Compte Colomé, et al. · Current Oncology · 3

1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations

2020 · A. Garcia-Alvarez, H. Verdaguer, et al. · Annals of Oncology · 2

97eP Predictors of recurrence and survival in endometrial cancer: A 22-year single-center cohort

2026 · E.G. Sardo, M. Alejo Sanchez, et al. · ESMO Open

98P Decoding survival in first-line advanced high-grade epithelial ovarian cancer (HGEOC): Real-world analysis of clinical and molecular prognostic factors

2025 · S.S. Andrés, I. Garcia Fructuoso, et al. · ESMO Open

1549P Molecular alterations (MA) with potential therapeutic implications in KRAS wild-type (WT) pancreatic cancer patients

2020 · D.A. Acosta Eyzaguirre, H. Verdaguer, et al. · Annals of Oncology

Works count: 9

Citation count: 189

H-index: 4

I10-index: 4